In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.
about
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidationPrediction of hepatic clearance in human from in vitro data for successful drug development.Evolution of drug metabolism: hitchhiking the technology bandwagon.S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics.Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceEffect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.Human clearance prediction: shifting the paradigm.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition.The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentiaChallenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.Optimization of a UDP-glucuronosyltransferase assay for trout liver S9 fractions: activity enhancement by alamethicin, a pore-forming peptide.Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate.Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.The effects of UDP-sugars, UDP and Mg2+on uridine diphosphate glucuronosyltransferase activity in human liver microsomes.In Vitro Drug Metabolism Using Liver Microsomes.In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.
P2860
Q31034463-95F3AD22-BBE2-4E5C-992B-7C9921866A02Q33437736-836BC23A-8CCB-4A1E-9721-03DDADF94DFDQ34941200-1C70D0EC-47EC-438B-B578-EB1BD17F7F4BQ35826926-4B02219B-3A7E-4F8F-A4E9-EE2EA82C8719Q35827481-77A0349C-F7E2-477D-B7E8-CB578554D10DQ35846898-D966FE7F-88C9-49C0-B205-7D46F3033262Q36725226-7E9AF75B-557E-49AD-A874-D500AAC64611Q36924729-C2B247CB-8312-4B0B-86F5-154545F5194BQ37230200-24510B66-F575-4BE5-A49B-43DC57803B20Q37397801-7D1DD2D3-F766-4701-A999-0813CC6E6290Q37554400-17B54B3F-C638-49D7-97A9-3275A8186BAEQ38798449-3E2BB99B-D04E-43F1-AA88-4FA9A159B466Q38799423-7523C397-1A78-4972-8361-DAD8D612AE54Q38811693-71297CBD-5CEE-4944-A2D4-77C691115AF7Q43268650-004B243A-A197-4AAD-873C-D1B475753AF1Q45345117-C7F8D3B5-4A9D-4E41-BBBB-04A5596FF9B6Q46584400-6727BEE8-5028-4FDA-9F81-1F32518484F1Q47228852-FE7A6B9A-A8FB-4FFF-A121-9C1D538E100BQ47293793-1C7D4E7D-C0C4-4EF6-A036-B4FBA2B7D3FAQ47853973-FAA42A73-F152-4B93-8CE3-3D02A65D0908Q50226493-9D4A2931-2175-4D05-8EC5-287A2C3FA60EQ51499112-7D74497E-F944-4358-8A0C-080D5CF74659Q51643121-51EB17F5-C440-4267-B382-66A8F45A94B1
P2860
In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
In vitro-in vivo correlations ...... he model substrate zidovudine.
@ast
In vitro-in vivo correlations ...... he model substrate zidovudine.
@en
type
label
In vitro-in vivo correlations ...... he model substrate zidovudine.
@ast
In vitro-in vivo correlations ...... he model substrate zidovudine.
@en
prefLabel
In vitro-in vivo correlations ...... he model substrate zidovudine.
@ast
In vitro-in vivo correlations ...... he model substrate zidovudine.
@en
P2860
P1476
In vitro-in vivo correlations ...... he model substrate zidovudine.
@en
P2093
John O Miners
P2860
P304
P356
10.1046/J.1365-2125.2002.01669.X
P407
P577
2002-11-01T00:00:00Z